Cabel, good point.

Perhaps, even if the vascular dementia sub study is just exploratory and possibly leading to more research for confirmation, if apabetalone achieves significant improvements in vascular dementia functions the media will finally deliver some sensational positive headlines for a change?

Something like "break through epigenetic drug apabetalone has achieved highly significant results in reduciing vascular dementia thus showing hope for a large and growing population of dementia patients........"

Just dreaming and still hoping. It would be great to get the press working in favour of RVX and this break through science.

Perhaps RVX PR people could even get some control of the cummunications agends. Reporters are always looking for help. Now I'm really dreaming.

GLTA

Toinv